Interestingly, a recent study reported that the protective effects of semaglutide and liraglutide on podocytes in DKD could be achieved via the regulation of the NLRP3 inflammasome pathway and the inhibition of the pyroptosis-related genes expression and inflammatory factors IL-1β and IL-18 [121]. This evidence concerns the gene NLRP3 and diabetic kidney disease.